Lauwers, & Masia, 2017). The prolonged average life of PD-1 inhibitors (Fessas, Lee, Ikemizu, & Janowitz, 2017) and the long-lasting tumor responses due to the persistence of immune activation (Robert et al., 2018; Schadendorf et al., 2017) may explain these delayed cutaneous adverse events. The pathogenesis of bullous pemphigoid (BP) induced by immunotherapy has not been clarified yet (Zhao, Hwang, Consuegra, Chou, & Fernandez-Penas, 2018). Diagnosis and management are similar to BP not associated with immunotherapy, taking into account that, in patients currently treated, early diagnosis and prompt treatment may allow therapy maintenance.